Immunogenicity, Efficacy, and Effectiveness of Two-Dose and Shorter Schedules of Hepatitis E Vaccine: A Systematic Review

被引:2
作者
Azam, Bilal [1 ]
Marti, Melanie [2 ]
Goel, Amit [3 ]
Aggarwal, Rakesh [1 ]
机构
[1] Jawaharlal Inst Postgrad Med Educ & Res, Dept Gastroenterol, Pondicherry 605006, India
[2] WHO, Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland
[3] Sanjay Gandhi Postgrad Inst Med Sci, Dept Hepatol, Lucknow 226014, India
关键词
hepatitis E; HEV; 239; shorter schedule; immunogenicity; efficacy;
D O I
10.3390/vaccines13010028
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis in adults. The schedule for HEV 239, the only approved anti-HEV vaccine, consists of three doses at 0, 1, and 6 months, which is unsuitable for use in emergency and outbreak situations where quick protection is desired. We, therefore, undertook a systematic review of data on immunogenicity, efficacy, and effectiveness of alternative accelerated schedules. Methods: Data sources on immunogenicity, efficacy, and effectiveness of the HEV 239 vaccine following accelerated schedules published between 22 January 2005 and February 2024 were identified from five electronic databases, and the relevant data were extracted. Results: The search identified seven relevant reports, including one phase II pre-licensure trial, three reports from the phase III licensure trial, and three post-licensure reports. In these studies, following administration of the HEV 239 vaccine in two doses at 0 and 1 month or a three-dose rapid (0, 7, and 21 days) schedule, anti-HEV antibody seroconversion rates were similar to and geometric mean concentrations of anti-HEV antibody were only slightly lower than those following the standard three-dose schedule. In individuals who were seropositive for anti-HEV antibodies at baseline, the antibody response persisted for several years irrespective of the number of vaccine doses, and in those who were seronegative at baseline, administration of two vaccine doses induced antibodies whose level remained substantially high till at least 13 months of follow-up. Administration of two doses was also associated with a high protective efficacy against HEV infection and associated disease. Conclusions: The available data indicate that two doses of HEV 239 administered one month apart confer sufficiently high antibody titers and protection for at least 13 months, a duration which should be adequate for its use as an outbreak control measure.
引用
收藏
页数:14
相关论文
共 18 条
[1]   Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial [J].
Chen, Z. ;
Lin, S. ;
Duan, J. ;
Luo, Y. ;
Wang, S. ;
Gan, Z. ;
Yi, H. ;
Wu, T. ;
Huang, S. ;
Zhang, Q. ;
Lv, H. .
CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (09) :1133-1139
[2]   Hepatitis E Epidemiology, Clinical Course, Prevention, and Treatment [J].
Goel, Amit ;
Aggarwal, Rakesh .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2020, 49 (02) :315-+
[3]   Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody [J].
Gu, Ying ;
Tang, Xuhua ;
Zhang, Xiao ;
Song, Cuiling ;
Zheng, Minghua ;
Wang, Kaihang ;
Zhang, Jun ;
Ng, Mun-Hon ;
Hew, Choy-Leong ;
Li, Shaowei ;
Xia, Ningshao ;
Sivaraman, J. .
CELL RESEARCH, 2015, 25 (05) :604-620
[4]   Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Huang, Shoujie ;
Zhang, Xuefeng ;
Su, Yingying ;
Zhuang, Chunlan ;
Tang, Zimin ;
Huang, Xingcheng ;
Chen, Qi ;
Zhu, Kongxin ;
Hu, Xiaowen ;
Ying, Dong ;
Liu, Xiaohui ;
Jiang, Hanmin ;
Zang, Xia ;
Wang, Zhongze ;
Yang, Changlin ;
Liu, Donglin ;
Wang, Yijun ;
Tang, Quan ;
Shen, Wentong ;
Cao, Huanhuan ;
Pan, Huirong ;
Ge, Shengxiang ;
Huang, Yue ;
Wu, Ting ;
Zheng, Zizheng ;
Zhu, Fengcai ;
Zhang, Jun ;
Xia, Ningshao .
LANCET, 2024, 403 (10429) :813-823
[5]   Immunization against Hepatitis E [J].
Innis, Bruce L. ;
Lynch, Julia A. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2018, 8 (11)
[6]   Hepatitis E virus infection [J].
Kamar, Nassim ;
Izopet, Jacques ;
Pavio, Nicole ;
Aggarwal, Rakesh ;
Labrique, Alain ;
Wedemeyer, Heiner ;
Dalton, Harry R. .
NATURE REVIEWS DISEASE PRIMERS, 2017, 3
[7]   A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults [J].
Kao, Carol M. ;
Rostad, Christina A. ;
Nolan, Lauren E. ;
Peters, Etza ;
Kleinhenz, Jennifer ;
Sherman, Jacob D. ;
Tippett, Ashley ;
Shih, J. Wai Kuo ;
Yildirim, Inci ;
Agbakoba, Vivien ;
Beresnev, Tatiana ;
Ballou, Cassandra ;
Kamidani, Satoshi ;
Karmali, Vinit ;
Natrajan, Muktha ;
Scherer, Erin M. ;
Rouphael, Nadine ;
Anderson, Evan J. .
JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (05) :1093-1101
[8]   Hepatitis E Virus Genome Structure and Replication Strategy [J].
Kenney, Scott P. ;
Meng, Xiang-Jin .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (01)
[9]   Epidemiology of Genotype 1 and 2 Hepatitis E Virus Infections [J].
Nelson, Kenrad E. ;
Labrique, Alain B. ;
Kmush, Brittany L. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (06)
[10]   Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan [J].
Nesbitt, Robin C. ;
Asilaza, Vincent Kinya ;
Gignoux, Etienne ;
Koyuncu, Aybuke ;
Gitahi, Priscillah ;
Nkemenang, Patrick ;
Duncker, Jetske ;
Antier, Zelie ;
Haile, Melat ;
Gakima, Primitive ;
Wamala, Joseph F. ;
Loro, Fredrick Beden ;
Biem, Duol ;
Rull, Monica ;
Azman, Andrew S. ;
Rumunu, John ;
Ciglenecki, Iza .
PLOS NEGLECTED TROPICAL DISEASES, 2024, 18 (01)